# Leslie A. Fecher

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/leslie-a-fecher/

## Facts

| Field | Value |
| --- | --- |
| Citations | 15,642 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 38 |
| i10-index | 59 |
| Last Known Institution | University of Michigan |
| OpenAlex ID | https://openalex.org/A5023622812 |
| ORCID iD | 0000-0002-6534-7457 |
| Works | 134 |

## Researcher papers

- [Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies](https://scholariq.org/papers/detection-of-circulating-tumor-dna-in-early-and-late-stage-human-malignancies/)
- [Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study](https://scholariq.org/papers/clinical-impact-of-covid-19-on-patients-with-cancer-ccc19-a-cohort-study/)
- [Neoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma](https://scholariq.org/papers/neoadjuvant-adjuvant-or-adjuvant-only-pembrolizumab-in-advanced-melanoma/)
- [Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression](https://scholariq.org/papers/host-expression-of-pd-l1-determines-efficacy-of-pd-l1-pathway-blockade-mediated/)
- [Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial](https://scholariq.org/papers/safety-pharmacokinetic-pharmacodynamic-and-efficacy-data-for-the-oral-mek/)
- [Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial](https://scholariq.org/papers/activity-of-the-oral-mek-inhibitor-trametinib-in-patients-with-advanced-melanoma/)
- [Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/)
- [Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor](https://scholariq.org/papers/phase-ii-study-of-the-mek1-mek2-inhibitor-trametinib-in-patients-with-metastatic/)
- [Combined MTOR and autophagy inhibition](https://scholariq.org/papers/combined-mtor-and-autophagy-inhibition/)
- [Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma](https://scholariq.org/papers/phase-i-trial-of-hydroxychloroquine-with-dose-intense-temozolomide-in-patients/)
- [Identifying Adolescent and Young Adults’ Preferences for Oncology Symptom Management Clinical Trial Participation](https://scholariq.org/papers/identifying-adolescent-and-young-adults-preferences-for-oncology-symptom/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [COVID-19 and healthcare impacts](https://scholariq.org/topics/covid-19-and-healthcare-impacts/)

## Researcher university

- [University of Michigan](https://scholariq.org/institutions/university-of-michigan/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.